A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...
We thank Yutaka Shimazu for his constructive comments on our HD21 trial.1 In the PET-2 positive cohort, 165 (69%) of 240 patients treated with brentuximab vedotin, etoposide, cyclophosphamide, ...
Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ...
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...
Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.
The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain ...
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback